Clene, Inc. (CLNN)
4.435
+0.12
(+2.66%)
USD |
NASDAQ |
Aug 24, 16:00
4.435
0.00 (0.00%)
After-Hours: 20:00
Clene Enterprise Value : 67.88M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 67.88M |
| August 20, 2026 | 68.51M |
| August 19, 2026 | 66.21M |
| August 18, 2026 | 64.94M |
| August 17, 2026 | 66.34M |
| August 14, 2026 | 65.58M |
| August 13, 2026 | 66.21M |
| August 12, 2026 | 64.68M |
| August 11, 2026 | 68.51M |
| August 10, 2026 | 78.61M |
| August 07, 2026 | 80.14M |
| August 06, 2026 | 80.91M |
| August 05, 2026 | 81.42M |
| August 04, 2026 | 80.14M |
| August 03, 2026 | 78.99M |
| July 31, 2026 | 76.76M |
| July 30, 2026 | 77.08M |
| July 29, 2026 | 72.99M |
| July 28, 2026 | 76.44M |
| July 27, 2026 | 82.44M |
| July 24, 2026 | 81.55M |
| July 23, 2026 | 82.70M |
| July 22, 2026 | 87.04M |
| July 21, 2026 | 87.43M |
| July 20, 2026 | 85.89M |
| Date | Value |
|---|---|
| July 17, 2026 | 88.32M |
| July 16, 2026 | 85.38M |
| July 15, 2026 | 89.60M |
| July 14, 2026 | 91.77M |
| July 13, 2026 | 94.33M |
| July 10, 2026 | 92.79M |
| July 09, 2026 | 92.54M |
| July 08, 2026 | 90.37M |
| July 07, 2026 | 90.88M |
| July 06, 2026 | 89.47M |
| July 02, 2026 | 90.62M |
| July 01, 2026 | 91.00M |
| June 30, 2026 | 91.32M |
| June 29, 2026 | 90.72M |
| June 26, 2026 | 87.49M |
| June 25, 2026 | 84.31M |
| June 24, 2026 | 83.72M |
| June 23, 2026 | 84.07M |
| June 22, 2026 | 85.48M |
| June 18, 2026 | 86.90M |
| June 17, 2026 | 85.95M |
| June 16, 2026 | 85.01M |
| June 15, 2026 | 84.07M |
| June 12, 2026 | 84.89M |
| June 11, 2026 | 81.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.190M |
| Brainstorm Cell Therapeutics, Inc. | 12.17M |
| Summit Therapeutics, Inc. | 9.767B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 87.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.42M |
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 13.51M |
| EPS Diluted (Quarterly) | -1.084 |
| Gross Profit Margin (Quarterly) | -332.2% |
| Profit Margin (Quarterly) | -14.92K% |
| Earnings Yield | -79.20% |
| Normalized Earnings Yield | -57.14 |